Patents by Inventor Roger D. Tung

Roger D. Tung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9840463
    Abstract: This invention relates to novel substituted styryl benzylsulfones that are multikinase inhibitors and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by an agent that inhibits kinases, such as phosphatidylinositol 3-kinase (PI3-K) and polo-like kinase (PLK-1).
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: December 12, 2017
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger D. Tung
  • Patent number: 9815763
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: November 14, 2017
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger D. Tung
  • Patent number: 9777009
    Abstract: The present invention in one embodiment provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: October 3, 2017
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Adam J. Morgan
  • Patent number: 9707218
    Abstract: This invention relates to novel pyrazole-substituted amino-heteroaryl compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of anaplastic lymphoma kinase (ALK).
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: July 18, 2017
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Bhaumik A. Pandya, Craig E. Masse, Ian Robert Silverman, Roger D. Tung
  • Patent number: 9708277
    Abstract: The invention relates to novel oxazolidinones their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering cholesterol ester transfer protein inhibitors.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: July 18, 2017
    Assignee: CONCERT PHARMACEUTICALS, INC.
    Inventor: Roger D. Tung
  • Publication number: 20170189406
    Abstract: The present invention in one embodiment provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.
    Type: Application
    Filed: December 14, 2016
    Publication date: July 6, 2017
    Inventor: Roger D. Tung
  • Publication number: 20170037449
    Abstract: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Application
    Filed: March 11, 2016
    Publication date: February 9, 2017
    Inventor: Roger D. Tung
  • Publication number: 20170027946
    Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.
    Type: Application
    Filed: October 12, 2016
    Publication date: February 2, 2017
    Inventors: Roger D. Tung, Julie F. Liu, Scott L. Harbeson
  • Publication number: 20170015670
    Abstract: The present invention in one embodiment provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.
    Type: Application
    Filed: July 27, 2016
    Publication date: January 19, 2017
    Inventors: Roger D. Tung, Adam J. Morgan
  • Patent number: 9540367
    Abstract: The present invention in one embodiment provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: January 10, 2017
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger D. Tung
  • Patent number: 9493463
    Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: November 15, 2016
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Julie F. Liu, Scott L. Harbeson
  • Patent number: 9492457
    Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: November 15, 2016
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Julie F. Liu, Scott L. Harbeson
  • Publication number: 20160326086
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Application
    Filed: April 11, 2016
    Publication date: November 10, 2016
    Inventors: Roger D. Tung, Adam J. Morgan, I. Robert Silverman
  • Patent number: 9422295
    Abstract: The present invention in one embodiment provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula (I) are as defined in the specification.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: August 23, 2016
    Assignee: CONCERT PHARMACEUTICALS, INC.
    Inventors: Roger D. Tung, Adam J. Morgan
  • Publication number: 20160159736
    Abstract: This invention relates to novel substituted styryl benzylsulfones that are multikinase inhibitors and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by an agent that inhibits kinases, such as phosphatidylinositol 3-kinase (PI3-K) and polo-like kinase (PLK-1).
    Type: Application
    Filed: January 29, 2016
    Publication date: June 9, 2016
    Inventor: Roger D. Tung
  • Patent number: 9328113
    Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentifylline and related compounds are beneficial.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: May 3, 2016
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Bhaumik Pandya, Scott L. Harbeson
  • Publication number: 20160115138
    Abstract: The invention relates to novel oxazolidinones their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering cholesterol ester transfer protein inhibitors.
    Type: Application
    Filed: December 28, 2015
    Publication date: April 28, 2016
    Inventor: Roger D. Tung
  • Patent number: 9309182
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: April 12, 2016
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Adam J. Morgan
  • Publication number: 20160083385
    Abstract: This invention in one embodiment is directed to a compound of Formula Ia; where the designation (R) indicates that the designated carbon has the (R) stereochemistry; and wherein Z1 is hydrogen or fluorine; Z2 is hydrogen, deuterium, or fluorine; Z3 is deuterium; Z4 is fluorine; m is an integer from 0 to 10; n is an integer from 0 to 2; provided that: the sum of m+n does not exceed 10; and when both Z1 and Z2 are hydrogen, the sum of m+n is greater than 0, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel.
    Type: Application
    Filed: December 3, 2015
    Publication date: March 24, 2016
    Inventors: Julie F. Liu, Scott L. Harbeson, Roger D. Tung
  • Publication number: 20160060263
    Abstract: This invention relates to novel compounds that are pyrazinoisoquinoline derivatives, and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel pyrazinoisoquinoline derivatives that are derivatives of praziquantel. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel.
    Type: Application
    Filed: November 4, 2015
    Publication date: March 3, 2016
    Inventors: Julie F. Liu, Scott L. Harbeson, Roger D. Tung